Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Substantial effort has been made over the last six decades to identify biomarkers for multiple
sclerosis that can improve disease diagnosis, predict disease progression, and improve …

Objective To measure CSF levels of biomarkers reflecting microglia and astrocytes
activation, neuroinflammation, and cerebrovascular changes and study their associations …

To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has
largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic …

Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-
like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort …

Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer's disease (AD)
patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic …

The prognostic role of cerebrospinal fluid molecular biomarkers determined in early
pathogenic stages of multiple sclerosis has yet to be defined. In the present study, we aimed …

Abstract Chitinase 3-like 1 (CHI3L1) is a secreted glycoprotein that mediates inflammation,
macrophage polarization, apoptosis, and carcinogenesis. The expression of CHI3L1 is …

Background: Neurofilament light chain (NfL) is a promising marker of disease
activity/treatment response in multiple sclerosis (MS), although its predictive value for long …

Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disease with a complex
clinical course characterized by inflammation, demyelination, and axonal degeneration …